info@birdgroup.be

Login

Research papers

Lancet Gastroenterol Hepatol. 2024 Feb 21:S2468-1253(24)00034-7. doi: 10.1016/S2468-1253(24)00034-7
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE)

The American journal of gastroenterology, 22 Jan. 2024, doi:10.14309/ajg.0000000000002635
Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial

Gastroenterology, 2023 Dec 12 doi:10.1053/j.gastro.2023.11.304
Dysbiosis and Associated Stool Features Improve Prediction of Response to Biological Therapy in Inflammatory Bowel Disease

Journal of Crohn's and Colitis, 2023 Nov 29:jjad195. doi: 10.1093/ecco-jcc/jjad195
A Core Outcome Set for inflammatory bowel diseases: development and recommendations for implementation in clinical practice through an international multi-stakeholder consensus process

Journal of Crohn's and Colitis, Volume 17, Issue 8, August 2023, Pages 1342–1353
Artificial Intelligence in Inflammatory Bowel Disease Endoscopy: Implications for Clinical Trials

N Engl J Med 2023; June: 388:2444-2455 DOI: 10.1056/NEJMoa2207940
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Journal of Crohn's and Colitis, Volume 17, Issue 7, July 2023, Pages 1139–1153.
Systematic Review with Meta-analysis: The Impact of Cancer Treatments on the Disease Activity of Inflammatory Bowel Diseases

Lancet Child Adolesc Health. 2023 Jun 27:S2352-4642(23)00136-0. doi: 10.1016/S2352-4642(23)00136-0. Epub ahead of print. PMID: 37390832.
Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents

Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network

‹
1
2
3
4
›